Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Torti

Showing results (131-140 of 263) with videos related to

Pageof 27
Sort By:
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Current HIV Research|February 22, 2008
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretroviralsCarlo Torti, Maria Eugenia Quiros-Roldan, Giuliana Cologni, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 26, 2024
Specialist training in infectious diseases in EuropeJon Salmanton-García, António Guerra Maio, Jean Paul Stahl, et al.
Antiviral Therapy|February 5, 2008
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori, Maria Paola Trotta, Patrizia Lorenzini, et al.
International Journal of Antimicrobial Agents|May 2, 2024
Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experienceAlessandro Russo, Sara Palma Gullì, Alessandro D'Avino, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Massimo Puoti, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Pageof 27

Showing results (131-140 of 263) with videos related to

Sort By:
Pageof 27
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Current HIV Research|February 22, 2008
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretroviralsCarlo Torti, Maria Eugenia Quiros-Roldan, Giuliana Cologni, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 26, 2024
Specialist training in infectious diseases in EuropeJon Salmanton-García, António Guerra Maio, Jean Paul Stahl, et al.
Antiviral Therapy|February 5, 2008
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutationAndrea Antinori, Maria Paola Trotta, Patrizia Lorenzini, et al.
International Journal of Antimicrobial Agents|May 2, 2024
Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experienceAlessandro Russo, Sara Palma Gullì, Alessandro D'Avino, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Massimo Puoti, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Pageof 27